Protease Inhibitor
48 drugs across 18 manufacturers|35 Generic,13 Brand
The Protease Inhibitor class contains 48 NDCs from 18 manufacturers (35 generic, 13 brand), at an average NADAC of $11.43 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
48
35G / 13B
Manufacturers
18
Avg $11.4287/unit
Avg 7d Change
-1.04%
Across 36 drugs with changes
7d Activity
of 48 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
18 manufacturers producing drugs in this therapeutic class(3 pricing outliers)
and 6 more manufacturers
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Camber Pharmaceuticals Inc. manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Darunavir market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Protease Inhibitor class?
The Protease Inhibitor class contains 48 NDCs from 18 manufacturers — 35 generic and 13 brand products.
What is the average price of Protease Inhibitor drugs?
The average NADAC for the Protease Inhibitor class is $11.4287 per unit across 48 NDCs.
Is generic cheaper than brand in the Protease Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $1.7692, versus $42.6685 for brand — brand products average about 24× the generic price.
Which manufacturers make Protease Inhibitor drugs?
18 manufacturers make drugs in the Protease Inhibitor class. Ranked by number of NDCs, the largest are Camber Pharmaceuticals Inc. (6), Aurobindo Pharma Limited (5), Janssen Products LP (4), AbbVie Inc. (4), E.R. Squibb & Sons, L.L.C. (3).
How has Protease Inhibitor pricing changed recently?
Over the past 7 days, 5 NDCs in this class rose and 31 fell, with a class-wide average change of -1.0%.